周宏灏院士集PDF|Epub|txt|kindle电子书版本网盘下载

周宏灏院士集PDF格式电子书版下载

注意：本站所有压缩包均有解压码： 点击下载压缩包解压工具

第一部分 奋斗历程1

中国遗传药理学的开拓者——记中国工程院院士周宏灏3

第二部分 学术贡献33

一、周宏灏院士的学术成就与学术思想35

二、周宏灏院士的主要学术论文42

Single-Dose Pharmacokinetics of Ceftriaxone in Healthy Chinese Adults42

Racial Differences in Drug Response Altered Sensitivity to and Clearance of Propranolol in Men of Chinese Descent as Compared with American Whites48

Interindividual Differences in β-receptor Density Contribute to Variability in Response toβ-adrenoceptor Antagonists56

Induction of Polymorphic 4’-hydroxylation of S-mephenytoin by Rifampicin60

Quinidine Reduces Clearance of（＋）-Propranolol More than（-）-Propranolol Through Marked Reduction in 4-Hydroxylation64

Differences in Plasma Binding of Drugs Between Caucasians and Chinese Subjects71

Increased Suppression of Exercise-Induced Increase in Renin by Propranolol in Chinese Subjects78

Lack of Effect of Ageing on the Stereochemical Disposition of Propranolol85

Differing Effect of Atropine on Heart Rate in Chinese and White Subjects89

Ethnic Differences in Response to Morphine94

Stereoselective Disposition of Carvedilol is Determined by CYP2D6100

The Elimination of Diazepam in Chinese Subjects is Dependent on the Mephenytoin Oxidation Phenotype107

In Vivo Inhibition of CYP2C19 But Not CYP2D6 by Fluvoxamine112

Genetic Polymorphisms of Debrisoquine and S-mephenytoin Oxidation Metabolism in Chinese Populations：a Meta-analysis116

Differences in the Incidence of the CYP2C19 Polymorphism Affecting the S-Mephenytoin Phenotype in Chinese Han and Bai Populations and Identification of a New Rare CYP2C19 Mutant Allele121

Evidence for the Effect of Gender on Activity of（S）-Mephenytoin 4’-Hydroxylase （CYP2C19）in A Chinese Population129

Meta-analysis of Phenotype and Genotype of NAT2 Deficiency in Chinese Populations134

The Induction Effect of Rifampicin on Activity of Mephenytoin 4’-hydroxylase Related to M1 Mutation of CYP2C19 and Gene Dose146

Evidence for Involvement of Polymorphic CYP2C19 and 2C9 in the N-demethylation of Sertraline in Human Liver Microsomes149

Effect of the Gene Dosage of CYP2C 19 on Diazepam Metabolism in Chinese Subjects157

Phenotypic Polymorphism and Gender-related Differences of CYP1A2 Activity in a Chinese Population162

5-Hydroxylation of Omeprazole by Human Liver Microsomal Fractions from Chinese Populations Related to CYP2C19 Gene Dose and Individual Ethnicity169

Ethnic Differences in Drug Metabolism179

Effect of the CYP2C19 Oxidation Polymorphism on Fluoxetine Metabolism in Chinese Healthy Subjects184

Pharmacokinetics of Sertraline in Relation to Genetic Polymorphism of CYP2C19189

Plasma Caffeine Metabolite Ratio（17X/137X） in Vivo Associated with G-2964A and C734A Polymorphisms of Human CYP1A2195

O-Dealkylation of Fluoxetine in Relation to CYP2C19 Gene Dose and Involvement of CYP3A4 in Human Liver Microsomes202

Assessment of Cytochrome P450 Activity by a Five-drug Cocktail Approach212

The Role of CYP2C19 in AmitriptylineN-demethylation in Chinese Subjects219

Inducibility of CYP1A2 by Omeprazole in Vivo Related to the Genetic Polymorphism of CYP 1A2225

Phenotypic Polymorphism of CYP2A6 Activity in a Chinese Population229

Histamine N-methyltransferase Gene Polymorphisms in Chinese and Their Relationship with Enzyme Activity in Erythrocytes235

Isozyme-specific Induction of Low-dose Aspirin on Cytochrome P450 in Healthy Subjects246

Gly389Arg Polymorphism of β1-adrenergic Receptor is Associated with the Cardiovascular Response to Metoprolol254

Pharmacokinetics of Citalopram in Relation to Genetic Polymorphism of CYP2C19261

The Distribution and Gender Difference of CYP3A Activity in Chinese Subjects268

St John’s Wort Induces Both Cytochrome P450 3A4-catalyzed Sulfoxidation and 2C19-dependent Hydroxylation of Omeprazole274

Iiell8Val Genetic Polymorphism of CYP3A4 and Its Effects on Lipid-lowering Efficacy of Simvastatin in Chinese Hyperlipidemic Patients281

Gender Specific Association of CYP2C9*3 with Hyperlipidaemia in Chinese288

β1-Adrenergic Receptor Polymorphisms Influence the Response to Metoprolol Monotherapy in Patients with Essential Hypertension291

Effect of SLCO1B1 Genetic Polymorphism on the Pharmacokinetics of Nateglinide301

Frequency of Genetic Polymorphisms of COX 1，GP Ⅲ a and P 2Y1 in a Chinese Population and Association with Attenuated Response to Aspirin307

SLCO1B1 521T→C Functional Genetic Polymorphism and Lipid-lowering Efficacy of Multiple-dose Pravastatin in Chinese Coronary Heart Disease Patients316

The Effect of Herbal Medicine Baicalin on Pharmacokinetics of Rosuvastatin，Substrate of Organic Anion-transporting Polypeptide 1B1322

Hepatic Nuclear Factor 1α Inhibitor Ursodeoxycholic Acid Influences Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 Substrate Rosuvastatin and Bilirubin329

Effects of Ginkgo Biloba Extract on the Pharmacokinetics of Bupropion in Healthy Volunteers334

Plant Polyphenol Curcumin Significantly Affects CYP1A2 and CYP2A6 Activity in Healthy，Male Chinese Volunteers340

Pharmacogenetics of Drugs Withdrawn from the Market349

三、周宏灏院士的主要学术著作358

药理学358

Textbook of Pharmacology360

Case Files TM Pharmacology363

Pharmacology365

遗传药理学（第2版）368

四、周宏灏院士重要学术报告、重要讲话369

Ethnic Differences in Drug Response369

Pharmacogenetic Research about Natural Medicine Effect of Natural Medicine on CYP450370

Ethnic Differences in Drug Metabolism372

Genetic Polymorphism of CYP2C19 in Chinese Populations373

Pharmacogenetics and Pharmacogenomics in Asian Populations and Impact on Clinical Pharmacology374

Racial Differences in Drug Response Reflect Differences in Distribution of Polymorphic Traits375

Pharmacogenetic and Pharmacogenomic Research in China376

Ethnicity，Genetics and Tailored Pharmacotherapy377

个体化药物治疗的研究与开发378

药物基因组学研究技术成果在药物临床评价中的应用379

在临床试验中不能忽视亚洲人群种族差异的基因多态性381

药物代谢酶基因多态性与个体化药物治疗382

个体化医学的实施与展望383

五、周宏灏院士学术年表384

周宏灏院士论文目录384

周宏灏院士专著目录424

周宏灏院士科研与教学成果目录425

周宏灏院士获国家发明专利目录427

第三部分 治学之道429

勤勉严谨做学问 情系祖国育桃李431

遗传药理学研究的先行者435

善于发现 勇于挑战——访临床药理学家周宏灏院士439

中国遗传药理学开拓者周宏灏：立志如山 行道如水445

周宏灏：中国个体化用药的“拓荒者”449

让患者用药更精确454

用药也需“量体裁衣”——访我国著名遗传药理学家周宏灏教授456

第四部分 大师风范461

一、感悟、经验与情怀463

做人 做事 做学问463

心系学子 桃李芬芳 以德服人 从严治学465

医学教育不能硬套综合大学管理体制——中国工程院院士周宏灏谈我国医学教育现状与改革467

春蚕到死丝方尽，人至期颐亦不休470

我的情操472

二、部分学生的代表性论文475

Effect of Asymmetric Dimethylarginine on Osteoblastic Differentiation475

Effect of SLCO1B1 Genetic Polymorphism on the Pharmacokinetics of Nateglinide476

Evidence for Involvement of Calcitonin Gene-Related Peptide in Nitroglycerin Response and Association with Mitochondrial Aldehyde Dehydrogenase-2 （ALDH2） Glu504Lys Polymorphism477

Molecular Population Genetics of Human CYP3A Locus：Signatures of Positive Selection and Implications for Evolutionary Environmental Medicine478

Coupling HPLC to on-line，Post-column（bio） Chemical Assays for High-resolution Screening of Bioactive Compounds from Complex Mixtures479

KCNJ 11 Lys23Glu and TCF7L2 rs290487（C/T） Polymorphisms affect Therapeutic Efficacy of Repaglinide in Chinese Patients with Type 2 Diabetes480

Inhibition of the Organic Anion-transporting Polypeptide 1B1 by Quercetin：An in Vitro and in Vivo Assessment481

Effect of eIF3a on Response of Lung Cancer Patients to Platinum-Based Chemotherapy by Regulating DNA Repair482

The Pregnane X Receptor Agonist St John’s Wort Has No Effects on the Pharmacokinetics and Pharmacodynamics of Repaglinide483

Effects of Lignans Extracted from Eucommia Ulmoides and Aldose Reductase Inhibitor Epalrestat on Hypertensive Vascular Remodeling484

ABCC2 Polymorphisms and Haplotype are Associated with Drug Resistance in Chinese Epileptic Patients485

Theragnostics Meets Traditional Chinese Medicine：Rational Prediction of Drug-herb Interactions486

Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer（NSCLC） Patients487

Protective Effects of Eucommia Lignans Against Hypertensive Renal Injury by Inhibiting Expression of Aldose Reductase488

Translational Regulation of RPA2 Via Internal Ribosomal Entry Site and by eIF3a489

Effect of NR3C2 Genetic Polymorphisms on the Blood Pressure Response to Enalapril Treatment490

The KCNH2 Genetic Polymorphism（1956，C＞T） Is a Novel Biomarker That Is Associated with CCB and α，β-ADR Blocker Response in EH Patients in China491

Polymorphism of ORM1 Is Associated with the Pharmacokinetics of Telmisartan492

Current Pharmacogenomic Studies on hERG Potassium Channels493

Deficiency of Multidrug and Toxin Extrusion 1 Enhances Renal Accumulation of Paraquat and Deteriorates Kidney Injury in Mice494

Effects of the Peroxisome Proliferator Activated Receptor-γ Coactivator-lα（PGC-1α） Thr394Thr and Gly482Ser Polymorphisms on Rosiglitazone Response in Chinese Patients with Type 2 Diabetes Mellitus495

Characterization and Analyses of Multidrug Resistance-associated Protein 1 （MRP1/ABCC 1）Polymorphisms in Chinese Population496

第五部分 社会影响497

我学者首次发现不同种族对药物的差异性499

Effectiveness of Drugs May be Influenced by Racial and Ethnic History500

深入了解中国人的心脏502

种族与药物的治疗效应503

β-受体阻滞药效应呈现种族差异505

药物效应的种族差异507

我国医学科技占世界之首成果巡礼509

Biomedicine510

DNA Chips Bring Personalized Medicine to China512

开拓国际临床药理新领域——记中国工程院院士周宏灏515

世界首张个体化用药基因芯片初步研制成功521

个体化用药成为焦点522

用多少药，问问你的遗传基因523

基因芯片：有助于药物治疗个体化524

用药也可“量体裁衣”525

周宏灏教授当选世界药理学联合会药物代谢学会理事526

省儿童医院聘请周宏灏为终身首席科学家527

引领人类个体化用药新时代的人——记我国著名临床与遗传药理学家周宏灏教授528

研发一体化做强湖南医药产业——访中国遗传药理学专家、中南大学临床药理研究所所长、中国工程院院士周宏灏教授538

种族差异、遗传及个体化药物治疗542

第六部分 人生风采543

成长历程545

教书育人547

学术交流550

珍贵合影553

人文情怀555